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ABSTRACT Doxycycline is the preferred recommended second-line 
treatment for the treatment of early syphilis. Recent reports showed 
a declining efficacy trend of doxycycline in treatment of early syphi-
lis. The aim of our study was to assess the serological response to the 
treatment for early syphilis with doxycycline compared with benzathine 
penicillin G and evaluate whether doxycycline is still an effective agent 
for the treatment of early syphilis. A record-based retrospective study 
was conducted. Patients were diagnosed with early syphilis in an sexu-
ally transmitted disease (STD) clinic from January 1, 2008 to December 
31, 2014. They were treated with a single dose of benzathine penicillin 
G 2.4MU or oral doxycycline 100 mg twice daily for 14 days. Pearson’s 
chi-squared test was used for data analysis. 601 cases were included in 
the final study sample: 105 (17.5%) patients received a 14-day course 
of doxycycline (doxycycline group), and 496 (82.5%) patients received 
single-dose benzathine penicillin G (BPG group). The serological re-
sponses at 6 months and 12 months after treatment were compared. no 
statistically significant differences were found between the two groups 
at 6 months (69.52% vs. 75.00%, P=0.245), and at 12 months (92.38% 
vs. 96.17%, P=0.115). Doxycycline is still an effective agent for the treat-
ment of early syphilis.
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INTRODUCTION
Syphilis is a complex systemic illness caused by 
the spirochete Treponema pallidum which is transmit-
ted both sexually and from mother to child (1). The 
incidence rate of syphilis has risen rapidly in China 
since 1978 (2,3), and it is one of the most common 
STDs in economically developed regions (4). The to-
tal reported incidence of syphilis in China increased 
from 8.71 cases/100,000 people in 2005 to 32.04 cas-
es/100,000 people in 2011, showing a yearly increase 
of 25.5% (5).
According to the treatment guidelines for sexually 
transmitted diseases (STDs) by the Centers for Disease 
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Control and Prevention (CDC) (2015) (6), benzathine 
penicillin G (BPG) is the preferred treatment agent for 
syphilis, and one dose of BPG (2.4 million units (MU)) 
administered intramuscularly is recommended for 
early syphilis (primary, secondary, and early latent 
syphilis). The major advantages of BPG treatment are 
its safety, effectiveness, and the favorable adherence 
to single dose schedule for early syphilis (7). Doxycy-
cline and cephalosporins are recommended as alter-
nate agents in non-pregnant patients if they are aller-
gic to penicillin or unable to tolerate treatment with 
BPG. Although more recent studies indicate a lower 
rate (<2.5%) of cross-reactivity between cephalospo-
rins and penicillin, the risk for penicillin cross-reactiv-
ity between most second-generation (cefoxitin) and 
all third generation cephalosporins (cefixime and cef-
triaxone) is negligible (6). Until now, there had been 
no related data to evaluate the efficacy of doxycycline 
in treatment of early syphilis in Shandong, China. We 
thus conducted a record-based retrospective study 
to compare the serological response rates of patients 
with early syphilis treated with BPG and doxycycline 
and to evaluate whether doxycycline is an effective 
agent for the treatment of early syphilis.
METHODS
Study setting
We conducted a record-based retrospective study. 
Participants were aged from 16 to 70 with early syphi-
lis (in the primary, secondary, or early latent stages) 
diagnosed at a STD clinic between January 1, 2008 
and December 31, 2014. This study was approved by 
the Human Medical and ethics Committee of the spe-
cialized institute.
Data collection
Diagnoses of primary, secondary, and early latent 
syphilis were made by trained clinicians at the sexually 
transmitted disease clinics on the basis of current US 
CDC criteria. Patient information about demographic 
characteristics, sexual history, symptoms, laboratory 
test results, diagnosis, and therapy were recorded in 
detail by clinicians.
Table 1. Baseline characteristics of patients in the benzathine penicillin G (BPG) treatment group and the 
doxycycline treatment group
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n % n %
Age (years)
  Median (IQR) 30 (24-40) 31 (25-41)
  10-19 39 7.9 4 3.8 0.382
  20-29 204 41.1 40 38.1
  30-39 125 25.2 31 29.5
  40+ 128 25.8 30 28.6
Sex 0.078
  Male 244 49.2 42 40.0
  Female 252 50.8 63 60.0
Ethnicity 0.751
  Han 480 96.8 98 93.3
  Minority 16 3.2 2 6.7
Stage of syphilis 0.711
  Primary 99 20.0 19 18.1
  Secondary 252 50.8 58 55.2
  early latent 145 29.2 28 26.7
RPR titer 0.313
≤1:4 50 10.1 10 9.5
1:8 40 8.1 12 11.4
    1:16 165 33.2 25 23.8
    1:32 106 21.4 28 26.7
  ≥1:64 135 27.2 30 28.6
Co-infection with other STDs 0.154
  Yes 90 18.1 13 12.4
  no 406 81.9 92 87.6
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Patients with a positive rapid plasma regain (RPR) 
test and Treponema pallidum particle assay (TPPA) 
test were candidates to be assessed. All patients in 
this study were treated with doxycycline 100 mg 
orally twice daily for 14 days or single-dose BPG 2.4 
MU. Only patients who were allergic to penicillin or 
who refused intramuscular BPG were treated with 
doxycycline.
Definitions
Serological response was defined as a decline of 
RPR titer by 4-fold or greater from the baseline value 
at 6 or 12 months of doxycycline or BPG treatment if 
initial RPR titer was 1:8 or higher. If RPR titer was 1:4, 
1:2, or 1:1 at baseline for primary syphilis or secondary 
syphilis, successful treatment was considered to be 
when the lesions disappeared and RPR turned to be 
negative after treatment. If follow-up was inadequate 
to determine the serological outcome of treatment, 
the patients would then be excluded. Patients with 
primary syphilis whose serological test results were 
nonreactive at the time of treatment were excluded, 
because this study focused on serological responses. 
All the subjects were HIV-negative and without other 
bacterial infections and received timely follow-up, 
because most HIV-positive patients were referred to 
the HIV Control and Prevention Center in Jinan.
Data analysis
Pearson’s chi-squared test or Fisher’s exact test 
were used to compare the categorical variables. 
Results were considered statistically significant at 
P<0.05 (2-tailed). Data were analyzed using SPSS 
(Version 17.0).
We compared the time to serological response 
between the patients receiving doxycycline and pa-
tients receiving BPG. Time to serological response 
was defined as the earliest date after therapy when 
a 4-fold drop in rapid plasma regain titer was docu-
mented. Figures were generated to estimate the se-
rological response rates at 6 months and 12 months 
after treatment (Figure 1) and the yearly changes of 
total efficacy rates during the study period (Figure 2).
RESULTS
Of the 747 primary syphilis cases reported during 
the study period, 601 cases were included in the final 
study sample. Overall, the median age of participants 
was 33 years old and 286 (47.6%) were men. Of these 
286 male patients, 8 patients identified themselves as 
man who had had sex with man (MSM); 118 patients 
(19.6%) had primary syphilis, 310 (51.6%) had second-
ary syphilis, and 173 (28.8%) had early latent syphilis. 
There was a similar distribution of patient character-
istics in each treatment group (Table 1). During the 
study period, 105 (17.5%) patients received a 14-day 
course of doxycycline, and 496 (82.5%) patients re-
ceived single-dose BPG. All patients in both groups 
were followed-up for at least 12 months.
We compared the serological response at 6 
months and 12 months after treatment. Table 2 pres-
ents the serological response and non-response rates 
in detail. There was no statistically significant differ-
ence between the doxycycline group and the penicil-
lin group at 6 months (69.52% vs. 75.00%, P=0.245), 
and at 12 months (92.38% vs. 96.17%, P=0.115) (Fig-
ure 1). The estimated median efficacy time was 106 
days (mean=127.4; range 30-296) in the doxycycline 
group and 132 days (mean=146.8; range 28-395) in 
the BPG group. The yearly efficacy trends of doxycy-
cline and BPG are shown in Figure 2. In total, there 
was no difference in the yearly efficacy of doxycycline 
(P=0.274).
DISCUSSION
Doxycycline is a recommended alternative in the 
treatment of patients with syphilis who are allergic 
to or intolerant of BPG. non-treponemal titers are 
the most widely used criterion in evaluating the re-
sponse to syphilis treatment (8-12). In recent years, 
clinical observations (13,14) have shown a declining 
efficacy of doxycycline in treatment of early syphilis. 
Table 2. Serological response and non-response rates in BPG and doxycycline group.
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BPG Doxycycline
n % n %
Titers drop 4-fold
Titers drop 8-fold
Titers drop 16-fold 
or greater
Serofast
236 47.58 39 37.14
106 21.37 28 26.67
135 27.21 30 28.57
69 13.91 15 14.28
Serological non-responders 19 3.83 8 7.62
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A multi-center observational study from Taiwan (13) 
showed a lower efficacy rate both in the penicillin and 
doxycycline group in the treatment of early syphilis in 
HIV-infected patients. li J et al. (14) also demonstrated 
a declining trend of doxycycline efficacy in the treat-
ment of early syphilis in Beijing, China. Of the 641 
early syphilis cases in the study, 606 (94.5%) received 
penicillin and 35 (5.5%) received doxycycline/tetracy-
cline. The efficacy rate in the doxycycline/tetracycline 
group was 82.9% (29/35). Our results were consistent 
with these recent studies and demonstrate that doxy-
cycline still appears to be an effective agent for the 
treatment of early syphilis.
Time to Serological Treatment Success
In a Baltimore study (15), successful treatment 
for primary, secondary, and early latent syphilis (de-
fined as a minimum 4-fold decrease in baseline rapid 
plasma reagin test titer by 9-13 months) was reported 
within 106 days for doxycycline, compared with 137 
days for penicillin. In the study by Wong et al. (16), the 
estimated median times were 43 days for doxycycline 
and 72 days for BPG. Our results, along with the re-
sults of these two studies, indicate that doxycycline 
had the same serological response time as BPG.
CONCLUSION AND LIMITATIONS
notably, the comparison of the serological re-
sponse rate at 6 months and 12 months after treat-
ment is one of the strengths of this study. However, 
there are still some limitations that need to be given 
full consideration. Firstly, because this was a retro-
spective study and treatment was not randomly al-
located, confounding factors such as age, sex, and 
combination with other STDs need to be considered. 
However, baseline characteristics of the two treat-
ment arms were comparable on the demographic 
and clinical characteristics examined. Secondly, treat-
ment adherence is another key question. There is 
no exact record on treatment adherence to ensure 
that full-dose treatment with a 14-day course of oral 
doxycycline was followed by all patients, and patients 
who followed the physician’s advice were more likely 
to return for follow-up serological testing. Addition-
ally, other factors, such as re-infection, serofast state, 
or even resistance to doxycycline might result in the 
lower efficacy of doxycycline in our study. Thirdly, our 
surveillance data had excluded HIV-infected patients, 
which may influence the serological response rate 
compared with patients with simple syphilis. In fact, 
there were 5 primary syphilis cases with HIV-infection 
that were excluded from the study and treated at a 
dedicated HIV clinic. Fourthly, the record was based 
on a questionnaire survey in the STD clinic. We pre-
sume the reason for the low rate of MSM in Shandong 
has something to do with the traditional culture. Most 
patients are ashamed or refuse to admit homosexual 
behavior in China.
In conclusion, the results of our study demon-
strate that doxycycline still appears to be an effective 
agent for the treatment of early syphilis.
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